Early Pharmacotherapy Resumption Post-Laparoscopic Sleeve Gastrectomy in Adolescents
Overview
This retrospective cohort analysis evaluated the safety, tolerability, and efficacy of early reinitiation of obesity pharmacotherapy following laparoscopic sleeve gastrectomy (LSG) in youth with severe obesity. Early pharmacotherapy resumption was associated with improved weight loss outcomes and reduced emotional overeating without compromising nutritional intake or tolerance.
Background
Pediatric obesity affects a growing proportion of youth, with severe obesity impacting approximately 7.6% in the U.S. Treatment modalities include lifestyle modification, pharmacotherapy, and metabolic and bariatric surgery (MBS), such as laparoscopic sleeve gastrectomy (LSG). While MBS achieves substantial weight loss, a subset of youth experience suboptimal outcomes or weight regain postoperatively. Current practice often involves discontinuing obesity pharmacotherapy perioperatively due to theoretical concerns, but emerging evidence suggests early reinitiation may improve long-term outcomes.
Data Highlights
Parameter
Early Pharmacotherapy Group
Standard Care Group
Number of Participants
29
21
Mean Age (years)
16.3 ± 2.1
16.7 ± 2.4
Baseline BMI (kg/m2)
46.2 ± 7.5
44.8 ± 6.9
Weight Loss at 3 Months (% change in BMI)
−14.5% ± 3.2%
−10.2% ± 3.8%
Reported Emotional Overeating Reduction
75%
38%
Adverse Events
Minimal, no serious complications
Minimal, no serious complications
Key Findings
Early reinitiation of obesity pharmacotherapy post-LSG was safe and well tolerated in adolescents.
Participants receiving early pharmacotherapy showed significantly greater BMI reduction at 3 months compared to standard care.
Emotional overeating decreased more substantially in the early pharmacotherapy group, despite reduced hunger sensations in both groups.
No negative impact on nutritional intake or gastrointestinal tolerance was observed with early pharmacotherapy resumption.
The majority of patients on early pharmacotherapy reported improved control over cravings and eating behaviors.
Clinical Implications
These findings support reconsidering the standard practice of delaying obesity pharmacotherapy after bariatric surgery in youth. Early pharmacotherapy resumption may enhance weight loss outcomes and mitigate emotional overeating without increasing adverse events. Clinicians should consider individualized shared decision-making to optimize postoperative obesity management protocols.
Conclusion
Early reinitiation of obesity pharmacotherapy following laparoscopic sleeve gastrectomy in adolescents appears safe, well tolerated, and effective in improving weight loss and reducing emotional overeating. This approach warrants further prospective study to refine pediatric obesity treatment strategies post-bariatric surgery.
References
Ogden et al. 2020 -- Prevalence of Childhood Obesity in the United States
Inge et al. 2021 -- Teen Longitudinal Assessment of Bariatric Surgery (Teen-LABS) Outcomes
Kelly et al. 2023 -- Pediatric Obesity Pharmacotherapy and Bariatric Surgery
